Krystal Biotech, Inc.
KRYS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $290,515 | $50,699 | $0 | $0 |
| % Growth | 473% | – | – | – |
| Cost of Goods Sold | $20,061 | $3,094 | $0 | $0 |
| Gross Profit | $270,454 | $47,605 | $0 | $0 |
| % Margin | 93.1% | 93.9% | – | – |
| R&D Expenses | $53,573 | $46,431 | $42,461 | $27,884 |
| G&A Expenses | $0 | $0 | $77,735 | $40,391 |
| SG&A Expenses | $113,686 | $98,401 | $77,735 | $40,391 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $37,500 | $12,500 | $25,000 | $0 |
| Operating Expenses | $204,759 | $157,332 | $145,196 | $68,275 |
| Operating Income | $65,695 | -$109,727 | -$145,196 | -$68,275 |
| % Margin | 22.6% | -216.4% | – | – |
| Other Income/Exp. Net | $29,661 | $122,624 | $5,221 | -$1,295 |
| Pre-Tax Income | $95,356 | $12,897 | -$139,975 | -$69,570 |
| Tax Expense | $6,197 | $1,965 | $0 | $0 |
| Net Income | $89,159 | $10,932 | -$139,975 | -$69,570 |
| % Margin | 30.7% | 21.6% | – | – |
| EPS | 3.12 | 0.4 | -5.49 | -3.13 |
| % Growth | 680% | 107.3% | -75.4% | – |
| EPS Diluted | 3 | 0.39 | -5.49 | -3.13 |
| Weighted Avg Shares Out | 28,592 | 27,154 | 25,492 | 22,197 |
| Weighted Avg Shares Out Dil | 29,740 | 27,752 | 25,492 | 22,197 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29,661 | $22,624 | $5,221 | $197 |
| Interest Expense | $0 | $0 | $0 | $1,492 |
| Depreciation & Amortization | $6,714 | $5,911 | $3,385 | $1,849 |
| EBITDA | $109,909 | -$91,316 | -$116,811 | -$66,229 |
| % Margin | 37.8% | -180.1% | – | – |